David Leslie Szekeres Heron Therapeutics, Inc. (HRTX) insider trading activity

David Leslie Szekeres is EVP, Chief Operating Officer of HERON THERAPEUTICS, INC. . Currently has a direct ownership of 33,754 shares of HRTX, which is worth approximately $37,804. The most recent transaction as insider was on Jul 13, 2023, when has been sold 2,012 shares (Common Stock) at a price of $1.31 per share, resulting in proceeds of $2,635. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 33.8K

0% 3M change

0% 12M change

Total Value Held $37,804

David Leslie Szekeres Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 13 2023	SELL Payment of exercise price or tax liability	$2,635 $1.31 p/Share	2,012 Reduced 5.63%	33,754 Common Stock
Jul 13 2023	BUY Exercise of conversion of derivative security	-	5,814 Added 13.98%	35,766 Common Stock
Apr 13 2023	SELL Payment of exercise price or tax liability	$5,794 $2.88 p/Share	2,012 Reduced 6.29%	29,952 Common Stock
Apr 13 2023	BUY Exercise of conversion of derivative security	-	5,814 Added 15.39%	31,964 Common Stock
Jan 13 2023	SELL Payment of exercise price or tax liability	$6,378 $3.17 p/Share	2,012 Reduced 7.14%	26,150 Common Stock
Jan 13 2023	BUY Exercise of conversion of derivative security	-	5,814 Added 17.11%	28,162 Common Stock
Oct 31 2022	BUY Other acquisition or disposition	$5,408 $3.27 p/Share	1,654 Added 6.89%	22,348 Common Stock
Oct 13 2022	SELL Payment of exercise price or tax liability	$7,565 $3.76 p/Share	2,012 Reduced 8.86%	20,694 Common Stock
Oct 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 20.39%	22,706 Common Stock
Jul 13 2022	SELL Payment of exercise price or tax liability	$6,056 $3.01 p/Share	2,012 Reduced 10.64%	16,892 Common Stock
Jul 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 23.52%	18,904 Common Stock
Apr 29 2022	BUY Other acquisition or disposition	$5,779 $3.84 p/Share	1,505 Added 10.31%	13,090 Common Stock
Apr 13 2022	SELL Payment of exercise price or tax liability	$12,213 $6.07 p/Share	2,012 Reduced 14.8%	11,585 Common Stock
Apr 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 29.95%	13,597 Common Stock
Jan 13 2022	SELL Payment of exercise price or tax liability	$16,700 $8.3 p/Share	2,012 Reduced 20.54%	7,783 Common Stock
Jan 13 2022	BUY Exercise of conversion of derivative security	-	5,814 Added 37.25%	9,795 Common Stock
Oct 13 2021	SELL Payment of exercise price or tax liability	$4,568 $10.55 p/Share	433 Reduced 9.81%	3,981 Common Stock
Oct 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 22.07%	4,414 Common Stock
Jul 13 2021	SELL Payment of exercise price or tax liability	$5,837 $13.48 p/Share	433 Reduced 12.04%	3,164 Common Stock
Jul 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 25.79%	3,597 Common Stock
Apr 30 2021	BUY Other acquisition or disposition	$21,267 $13.9 p/Share	1,530 Added 39.46%	2,347 Common Stock
Apr 13 2021	SELL Payment of exercise price or tax liability	$7,214 $16.66 p/Share	433 Reduced 34.64%	817 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	-	1,250 Added 50.0%	1,250 Common Stock
Jan 14 2021	SELL Open market or private sale	$14,960 $18.09 p/Share	827 Reduced 100.0%	0 Common Stock
Jan 13 2021	SELL Payment of exercise price or tax liability	$7,682 $18.16 p/Share	423 Reduced 33.84%	827 Common Stock

Also insider at

VLON

Vallon Pharmaceuticals, Inc. Healthcare

Director

DLS